Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BridgeBio Pharma, Inc. (BBIO) had Revenue of $110.56M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$110.56M
Net Income	$-181.90M
Cost of Goods Sold	$3.65M
Gross Profit	$106.91M
Operating Expenses	$244.84M
Operating Income	$-134.28M
Non-Operating Income/Expense	$-47.38M
Pre-Tax Income	$-181.66M
Normalized Pre-Tax Income	$-181.66M
Income after Taxes	$-183.76M
Income from Continuous Operations	$-183.76M
Consolidated Net Income/Loss	$-183.76M
Normalized Income after Taxes	$-183.76M
EBIT	$-134.28M
EBITDA	$-132.96M
Weighted-Average Shares Outstanding (Basic)	190.52M
Weighted-Average Shares Outstanding (Diluted)	190.52M
Earnings per Share (EPS) (Basic)	$-0.95
Earnings per Share (EPS) (Diluted)	$-0.95
Balance Sheet Financials
Current Assets	$912.28M
Property, Plant, and Equipment	$6.11M
Long-Term Assets	$167.91M
Total Assets	$1.08B
Current Liabilities	$175.85M
Long-Term Debt	$1.85B
Long-Term Liabilities	$2.68B
Total Liabilities	$2.86B
Common Equity	$-1.78B
Tangible Shareholders Equity	$-1.81B
Shareholders Equity	$-1.78B
Common Shares Outstanding	191.16M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-279.92M
Cash Flow from Investing Activities	$-14.60M
Cash Flow from Financial Activities	$362.37M
Beginning Cash	$683.24M
End Cash	$751.10M
Increase/Decrease in Cash	$67.86M
Stock-Based Compensation	$63.12M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.19
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	25.84
Debt to Equity Ratio	-1.04
Gross Margin	96.70%
Operating Margin	-121.45%
EBIT Margin	-121.45%
EBITDA Margin	--
Pre-Tax Profit Margin	-164.30%
Profit Margin	-164.52%
Free Cash Flow	$-280.51M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.10
Inventory Turnover	0.20
Receiveable Turnover	1.44
Days Sales in Receivables	62.57
Return on Equity	10.34%
Return on Tangible Equity	10.17%
Return on Assets	-17.01%
Return on Investments	-256.70%
Book Value Per Share	$-9.30
Free Cash Flow per Share	$-1.47
Operating Cash Flow per Share	$-1.47

Data from Zacks Investment Research, Inc.